<DOC>
	<DOCNO>NCT02338635</DOCNO>
	<brief_summary>Peritoneal fibrosis one major cause technical failure patient peritoneal dialysis ( PD ) long period time . Although exact mechanism peritoneal damage PD still remain unclear , generation Endoplasmic reticulum ( ER ) stress may responsible progressive membrane dysfunction . Ursodeoxycholic acid ( URSA ) powerful inhibitor ER stress protect peritoneal fibrosis peritoneal dialysis investigator in-vitro study . In study researcher investigate hypothesis URSA protect peritoneal membrane damage .</brief_summary>
	<brief_title>Effect Ursodeoxycholic Acid Peritoneal Function Patients Peritoneal Dialysis</brief_title>
	<detailed_description>Ursodeoxycholic acid ( URSA ) know relatively safe beneficial peritoneal dialysis patient dose 300 mg per day . Patients randomly assign URSA placebo group prescribe accord protocol . At 2 6 month , Peritoneal equilibrium test ( PET ) perform blood sampling .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Maintenance peritoneal dialysis least 3 month Patients able willing understand , sign date inform consent document , authorize access protect health information Episode peritonitis least 3 month Episodes admission due disease lease 3 month Liver disease Allergic history Ursodeoxycholic acid Nausea vomit Ursodeoxycholic acid</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>ER stress</keyword>
	<keyword>Peritoneal Dialysis</keyword>
</DOC>